| Literature DB >> 32226694 |
Manar Hasabullah1, Fatamah Kahtani1, Tasneem Balkhoyor1, Lama Al-Harbi1, Abdulhalim J Kinsara1.
Abstract
Introduction Several cardiovascular risk calculators are available online to measure the probability of developing cardiovascular disease (CVD) without defining the appropriate population. In the current study, four risk assessment instruments were investigated with Saudi Arabian patients with CVD to identify the instrument with the best predictability. The chosen instruments were the Framingham Risk Score (FRS), Systematic Coronary Risk Evaluation (SCORE), American College of Cardiology/American Heart Association (ACC/AHA) Atherosclerotic Cardiovascular Disease Risk Estimator, and the United Kingdom score which is called QRISK®. Methods Saudi patients, 40 years and older, with acute coronary syndrome, were recruited. Data related to age, gender, ethnicity, height, weight, systolic blood pressure, total cholesterol, high-density lipoprotein (HDL), smoking status, diabetes mellitus, rheumatoid arthritis, chronic kidney disease, atrial fibrillation, heart attack in a first-degree relative, and use of antihypertensive treatment were recorded. Results Out of 129 patients, the ACC/AHA had higher predictability with low risk (26.3%) and high risk (66.7%) groups. The QRISK® was highly applicable (95.3%); however, the SCORE was not considered applicable (22.5%). Conclusion The QRISK® is easy to implement and applicable in a population-based study, but the ACC/AHA is superior in predicting individuals with a high risk of CVD.Entities:
Keywords: american college of cardiology/american heart association atherosclerotic cardiovascular disease risk estimator; framingham risk score; qrisk; risk assessment tools; saudi arabia; score; systematic coronary risk evaluation
Year: 2020 PMID: 32226694 PMCID: PMC7096078 DOI: 10.7759/cureus.7093
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Baseline characteristics of participants (n=129)
BMI - body mass index; DM - diabetes mellitus; HTN - hypertension; SBP - systolic blood pressure; DBP - diastolic blood pressure; HDL - high-density lipoprotein; SD - standard deviation
| Study variables | n (%) |
| Gender | |
| Male | 91 (70.5%) |
| Classification of BMI | |
| Normal | 27 (20.9%) |
| Overweight | 42 (32.6%) |
| Obese | 60 (46.5%) |
| Smoking | 26 (20.2%) |
| DM | 103 (79.8%) |
| Family history of heart attack/angina | 38 (29.5%) |
| Chronic kidney disease | 23 (17.8%) |
| Atrial fibrillation | 07 (05.4%) |
| Treatment of HTN | 101 (78.3%) |
| Rheumatoid arthritis | 07 (05.4%) |
| mean ± SD | |
| Age in years | 63.1 ± 10.7 |
| SBP (mmHg) | 124.7 ± 19.9 |
| DBP (mmHg) | 65.3 ± 14.4 |
| Total cholesterol (mmol/L) | 04.1 ± 01.3 |
| HDL (mmol/L) | 0.9 ± 0.3 |
Cardiovascular risk score according to different assessment tools (n=129)
*Some subjects had more than one reason for exclusion
AHA/ACC – American Heart Association/American College of Cardiology; FRS – Framingham Risk Score
| Risk classification | AHA/ACC: n (%) | Euro-SCORE; n (%) | FRS; n (%) | QRISK®; n (%) |
| Cardiovascular risk level applicability | 57 (44.2%) | 29 (22.5%) | 38 (29.5%) | 123 (95.3%) |
| Low risk (LR) | 15 (26.3%) | 4 (13.8%) | 6 (15.8%) | 16 (13.0%) |
| Moderate risk (MR) | 4 (7.0%) | 16 (55.2%) | 13 (34.2%) | 30 (24.4%) |
| High risk (HR) | 38 (66.7%) | 9 (31.0%) | 19 (50.0%) | 77 (62.6%) |
| Nonapplicable | 72 (55.8%) | 100 (77.5%) | 91 (70.5%) | 6 (4.7%) |
| Excluded by: | ||||
| Age limitation | 10 (7.7%) | 0 (0.0%) | 2* (1.5%) | 6 (4.7%) |
| Cholesterol level | 62 (48.0%) | 65* (50.4%) | 89* (68.9%) | 0 (0.0%) |
| Blood pressure level | 0 (0.0%) | 50* (38.7%) | 1* (0.7%) | 0 (0.0%) |
Relationship between socio demographic factors and CVD assessment tools (n=129)
AHA/ACC – American Heart Association/American College of Cardiology; FRS – Framingham Risk Score; LR - low risk; MR - moderate risk; HR – high risk; BMI – body mass index; DM – diabetes mellitus; HTN - hypertension; CVD - cardiovascular disease
† Not applicable were excluded from the comparison
P-value has been calculated using Chi-square test
** Significant at p≤0.05 level
| Factor | AHA/ACC † | SCORE † | FRS † | QRISK® † | ||||||||
| LR (%) | MR (%) | HR (%) | LR (%) | MR (%) | HR (%) | LR (%) | MR (%) | HR (%) | LR (%) | MR (%) | HR (%) | |
| Gender | ||||||||||||
| Male | 46.7% | 75.0% | 73.7% | 25.0% | 62.5% | 88.9% | 50.0% | 46.2% | 73.7% | 75.0% | 66.7% | 75.3% |
| Female | 53.3% | 25.0% | 26.3% | 75.0% | 37.5% | 11.1% | 50.0% | 53.8% | 26.3% | 25.0% | 33.3% | 24.7% |
| P-value | 0.160 | 0.076 | 0.249 | 0.652 | ||||||||
| Age group in years | ||||||||||||
| ≤60 years old | 46.7% | 0 | 44.7% | 100% | 43.8% | 11.1% | 50.0% | 76.9% | 31.6% | 25.0% | 50.0% | 39.0% |
| >60 years old | 53.3% | 100% | 55.3% | 0 | 56.2% | 88.9% | 50.0% | 23.1% | 68.4% | 75.0% | 50.0% | 61.0% |
| P-value | 0.208 | 0.011 ** | 0.042 ** | 0.248 | ||||||||
| Classification of BMI | ||||||||||||
| Normal | 0 | 0 | 26.3% | 25.0% | 25.0% | 33.3% | 33.3% | 15.4% | 31.6% | 12.5% | 13.3% | 24.7% |
| Overweight | 40.0% | 75.0% | 26.3% | 0 | 25.0% | 11.1% | 16.7% | 38.5% | 26.3% | 31.2% | 36.7% | 31.2% |
| Obese | 60.0% | 25.0% | 47.4% | 75.0% | 50.0% | 55.6% | 50.0% | 46.2% | 42.1% | 56.2% | 50.0% | 44.2% |
| P-value | 0.069 | 0.742 | 0.784 | 0.625 | ||||||||
| Smoking | ||||||||||||
| Yes | 0 | 0 | 23.7% | 0 | 12.5% | 0 | 33.3% | 15.4% | 26.3% | 0 | 16.7% | 27.3% |
| No | 93.3% | 50.0% | 68.4% | 100% | 87.5% | 77.8% | 66.7% | 76.9% | 57.9% | 93.8% | 76.7% | 62.3% |
| Ex-smoker | 06.7% | 50.0% | 07.9% | 0 | 0 | 22.2 | 0 | 07.7% | 15.8% | 06.2% | 06.7% | 10.4% |
| P-value | 0.017 ** | 0.182 | 0.676 | 0.105 | ||||||||
| DM | ||||||||||||
| Yes | 66.7% | 100% | 76.3% | 75.0% | 75.0% | 77.8% | 16.7% | 61.5% | 84.2% | 81.2% | 76.7% | 80.5% |
| No | 33.3% | 0 | 23.7% | 25.0% | 25.0% | 22.2% | 83.3% | 38.5% | 15.8% | 18.8% | 23.3% | 19.5% |
| P-value | 0.379 | 0.987 | 0.009 ** | 0.893 | ||||||||
| History of angina | ||||||||||||
| Yes | 33.3% | 25.0% | 42.1% | 50.0% | 37.5% | 33.3% | 0 | 23.1% | 36.8% | 31.2% | 20.0% | 32.5% |
| No | 66.7% | 75.0% | 57.9% | 50.0% | 62.5% | 66.7% | 100% | 76.9% | 63.2% | 68.8% | 80.0% | 67.5% |
| P-value | 0.710 | 0.848 | 0.192 | 0.437 | ||||||||
| Treatment of HTN | ||||||||||||
| Yes | 86.7% | 75.0% | 73.7% | 100% | 81.2% | 77.8% | 66.7% | 69.2% | 57.9% | 81.2% | 76.7% | 77.9% |
| No | 13.3% | 25.0% | 26.3% | 0 | 18.8% | 22.2% | 33.3% | 30.8% | 42.1% | 18.8% | 23.3% | 22.1% |
| P-value | 0.594 | 0.602 | 0.793 | 0.937 | ||||||||